SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics resubmitted its Biologics License Application…

Outlook Therapeutics, Inc. · 8-K filed Jun 1, 2026 at 09:15 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 1, 2026 at 09:15 ET

Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) to the FDA for the treatment of neovascular age-related macular degeneration (nAMD). The FDA Office of New Drugs previously concluded that substantial evidence of effectiveness has been established, and this is a Class 1 resubmission with a PDUFA decision expected within 60 days.

  • BLA resubmitted to FDA on June 1, 2026 for ONS-5010/LYTENAVA (bevacizumab-vikg) for nAMD.
  • FDA Office of New Drugs concluded substantial evidence of effectiveness has been established; no additional trials required.
  • Class 1 resubmission with PDUFA decision expected within 60 days of FDA receipt.
  • Product already has Marketing Authorization in the EU and UK; commercial launch commenced in Germany, Austria, and the UK.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access